Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke

Experimental Neurology

Volumn 255, Issue , 2014, Pages 56-62

  Houng, Aiilyan K ^a   Wang, Dong ^a   Reed, Guy L ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; Edema; Fibrinolysis; Hemorrhage; Mortality; Stroke; Thrombosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL;

APOPTOSIS; EDEMA; FIBRINOLYSIS; HEMORRHAGE; MORTALITY; STROKE; THROMBOSIS;

ALPHA-2-ANTIPLASMIN; ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; MALE; MICE; MICE, INBRED C57BL; NEURONS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84896302928     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.02.009     Document Type: Article

References (29)

1. Aoki T., Sumii T., Mori T., Wang X., Lo E.H. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002, 33:2711-2717.
2. Butte A.N., Houng A.K., Jang I.K., Reed G.L. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. Circulation 1997, 95:1886-1891.
3. Cesarman-Maus G., Hajjar K.A. Molecular mechanisms of fibrinolysis. Br. J. Haematol. 2005, 129:307-321.
4. Chimowitz M.I. Endovascular treatment for acute ischemic stroke-still unproven. N. Engl. J. Med. 2013, 368:952-955.
5. del Zoppo G.J., Koziol J.A. Recanalization and stroke outcome. Circulation 2007, 115:2602-2605.
6. Donnan G.A., Davis S.M., Parsons M.W., Ma H., Dewey H.M., Howells D.W. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat. Rev. Neurol. 2011, 7:400-409.
7. Furuya K., Kawahara N., Kawai K., Toyoda T., Maeda K., Kirino T. Proximal occlusion of the middle cerebral artery in C57Black6 mice: relationship of patency of the posterior communicating artery, infarct evolution, and animal survival. J. Neurosurg. 2004, 100:97-105.
8. Hara T., Mies G., Hossmann K.A. Effect of thrombolysis on the dynamics of infarct evolution after clot embolism of middle cerebral artery in mice. J. Cereb. Blood Flow Metab. 2000, 20:1483-1491.
9. Kawashita E., Kanno Y., Asayama H., Okada K., Ueshima S., Matsuo O., Matsuno H. Involvement of alpha2-antiplasmin in dendritic growth of hippocampal neurons. J. Neurochem. 2013, 126:58-69.
10. Kilic E., Hermann D.M., Hossmann K.A. Recombinant tissue-plasminogen activator-induced thrombolysis after cerebral thromboembolism in mice. Acta Neuropathol. 2000, 99:219-222.
11. King S.M., McNamee R.A., Houng A.K., Patel R., Brands M., Reed G.L. Platelet dense-granule secretion plays a critical role in thrombosis and subsequent vascular remodeling in atherosclerotic mice. Circulation 2009, 120:785-791.
12. Lees K.R., Bluhmki E., von Kummer R., Brott T.G., Toni D., Grotta J.C., Albers G.W., Kaste M., Marler J.R., Hamilton S.A., Tilley B.C., Davis S.M., Donnan G.A., Hacke W., Allen K., Mau J., Meier D., del Zoppo G., De Silva D.A., Butcher K.S., Parsons M.W., Barber P.A., Levi C., Bladin C., Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703.
13. Lijnen H.R., Okada K., Matsuo O., Collen D., Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999, 93:2274-2281.
14. Marti-Fabregas J., Borrell M., Cocho D., Belvis R., Castellanos M., Montaner J., Pagonabarraga J., Aleu A., Molina-Porcel L., Diaz-Manera J., Bravo Y., Alvarez-Sabin J., Davalos A., Fontcuberta J., Marti-Vilalta J.L. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology 2005, 65:366-370.
15. Matsuno H., Okada K., Ueshima S., Matsuo O., Kozawa O. Alpha2-antiplasmin plays a significant role in acute pulmonary embolism. J. Thromb. Haemost. 2003, 1:1734-1739.
16. Mergenthaler P., Meisel A. Do stroke models model stroke?. Dis. Model. Mech. 2012, 5:718-725.
17. Mutch N.J., Thomas L., Moore N.R., Lisiak K.M., Booth N.A. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J. Thromb. Haemost. 2007, 5:812-817.
18. Nagai N., De Mol M., Lijnen H.R., Carmeliet P., Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999, 99:2440-2444.
19. Orset C., Macrez R., Young A.R., Panthou D., Angles-Cano E., Maubert E., Agin V., Vivien D. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 2007, 38:2771-2778.
20. Overgaard K., Sereghy T., Boysen G., Pedersen H., Diemer N.H. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke 1992, 23:1167-1173. (discussion 1174).
21. Reed G.L., Houng A.K. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999, 99:299-304.
22. Reed G.L., Matsueda G.R., Haber E. Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis. Circulation 1990, 82:164-168.
23. Reed G.L., Matsueda G.R., Haber E. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1114-1118.
24. Saleem S., Li R.C., Wei G., Dore S. Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J. Neurosci. Res. 2007, 85:2433-2440.
25. Sazonova I.Y., Thomas B.M., Gladysheva I.P., Houng A.K., Reed G.L. Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate. J. Thromb. Haemost. 2007, 5:2087-2094.
26. Suri M.F., Yamagishi K., Aleksic N., Hannan P.J., Folsom A.R. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc. Dis. 2010, 29:497-502.
27. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 1990, 10:290-293.
28. Tsirka S.E., Rogove A.D., Bugge T.H., Degen J.L., Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 1997, 17:543-552.
29. Weitz J.I., Leslie B., Hirsh J., Klement P. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J. Clin. Invest. 1993, 91:1343-1350.